In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duloxetine Drug Interactions Are Issue For Yentreve, But Not For Cymbalta

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Review documents for Cymbalta note a difference in opinion regarding the significance of drug interactions between FDA’s review divisions for the two duloxetine indications – major depressive disorder and stress urinary incontinence (under the trade name Yentreve).

You may also be interested in...



Cymbalta Liver Safety Was Key Review Issue Delaying Lilly’s Antidepressant

Initial approval of Lilly’s Cymbalta appears to have been delayed primarily by concerns over liver toxicity, FDA review documents for the serotonin-norepinephrine reuptake inhibitor show.

Cymbalta Liver Safety Was Key Review Issue Delaying Lilly’s Antidepressant

Initial approval of Lilly’s Cymbalta appears to have been delayed primarily by concerns over liver toxicity, FDA review documents for the serotonin-norepinephrine reuptake inhibitor show.

FDA Has 19 Applications Remaining With User Fees In 2004: 7 NMEs, 1 BLA

With seven first-cycle new molecular entities with user fee deadlines in November and December, FDA could surpass the total number of new molecular entities approved in 2003.

Related Content

Topics

UsernamePublicRestriction

Register

PS002701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel